New antibiotic design could help treat drug-resistant infections

A new design strategy targets a common resistance mechanism

Researchers led by King’s College London have described a new approach to antibiotic design that aims to overcome one of bacteria’s most effective defense mechanisms: efflux pumps. These molecular pumps eject antibiotics from bacterial cells before drug concentrations can rise high enough to kill them.

The study, published in the Journal of Medicinal Chemistry, introduces what the team calls an Efflux Resistance Breaker, or ERB, approach. Instead of pairing antibiotics with separate efflux pump inhibitors, the researchers say they can redesign the antibiotic molecule itself so that it is less easily pumped out.

Why this matters now

Antimicrobial resistance continues to rise while the supply of truly new antibiotics remains limited. The source text quotes Professor Khondaker Miraz Rahman as saying the number of genuinely new antibiotics in development remains worryingly low. That makes strategies that extend the usefulness of existing drug classes especially valuable.

The ERB concept is important because it shifts resistance-fighting properties into the structure of the drug. In practical terms, the antibiotic is designed to protect itself from expulsion. The result, according to the research summary, is that the drug stays inside bacterial cells at higher concentrations and can regain the ability to kill bacteria even when resistance mechanisms are active.

From workaround to built-in protection

Previous efforts have often tried to block efflux pumps using an added inhibitor. The King’s-led work takes a different route. By building the resistance-breaking property directly into the antibiotic, the treatment strategy becomes more integrated and potentially more durable.

That design philosophy could matter beyond a single compound or bacterial species. The researchers argue that the approach may support both the discovery of new antibiotics and the revival of older ones that have lost effectiveness over time because bacteria evolved to evade them.

Potential impact on the pipeline

One of the strongest implications in the source text is not only therapeutic but developmental. If ERB-style thinking can be incorporated early in medicinal chemistry, it may change how antibiotic candidates are screened and optimized. Rather than asking only whether a compound can kill bacteria under ideal conditions, researchers could ask from the outset whether it can also remain inside the cell in the face of known resistance behavior.

That is a meaningful shift because bacterial resistance often undermines promising molecules after they look effective in simpler tests. A design rule that anticipates one of the most common escape routes could improve the odds that candidate drugs survive the path toward clinical relevance.

A pragmatic advance in a difficult field

The study does not solve antimicrobial resistance by itself, and the source package does not claim that it does. What it offers is a concrete, chemically grounded tactic for making antibiotics harder for bacteria to defeat. In a field where major breakthroughs are rare and resistance moves quickly, even incremental design advantages can become strategically important.

For health systems and drug developers, the appeal is obvious. A method that helps revive older antibiotic classes while also guiding better new ones could stretch scarce innovation further. That makes the ERB approach less of a narrow lab result and more of a potentially useful framework for rebuilding an antibiotic pipeline under pressure.

This article is based on reporting by Medical Xpress. Read the original article.